Kennedy Schaal is the CEO of Rejuve.bio, a biotech company with the goal of solving aging by building AGI for drug discovery.
In this episode, Kennedy Schaal introduces her company Rejuve.bio which comes out of the SingularityNet. Kennedy Schaal and I discuss the intersection of data, AI, and collaboration in the longevity sector. We explore the importance of community engagement, the potential for shared data to advance research, and the role of marketing in promoting longevity initiatives. Kennedy emphasizes the need for a collective approach to solving aging-related issues and shares her personal commitment to community service and the arts.
- Zelar City Website
- What is Zelar City?
- This episode on YouTube
00:00 Intro to Rejuve.bio, Kennedy Schaal, and SingularityNet
00:38 The Methuselah Fruit Fly experiment
01:05 Why Kennedy Schaal is working in Longevity
05:38 Why Kennedy Schaal is working with SingularityNet
09:40 What is the scope of Rejuve Biotech?
10:44 Licensing model of the target discovery platform by Rejuve.bio
13:14 How does Rejuve.bio fit in SingularityNets vision of descentralization? (Rejuve.ai)
18:40 How are Rejuve.bio and Rejuve.ai connected?
20:05 How is it like to build a Biotech company
23:27 Kennedys experience with remote work in a biotech company
24:52 The hardest part of developing Rejuve.bio
27:22 The role of DeSci for solving aging
32:01 The role of Pop-up cities like Zelar for advancing longevity research
34:04 Kennedys advice to people starting out in longevity
36:56 Kennedy Schaals biggest learning from having a longevity company
38:28 What does Kennedy Schaal do in her free-time
41:29 How long do you want to live? @ Kennedy Schaal
43:28 Next interview and Links